FLAGSTAFF, Ariz., July 13, 2017 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES), a developer of proprietary technologies for managing animal pest populations through fertility control, announced today that data sets will be presented at the 50th Annual Meeting of the Society for the Study of Reproduction (SSR) this week in Washington, D.C. demonstrating the reduction of fertility in mice with a unique and targeted formulation of SenesTech's proprietary active ingredients and delivery technology.
Dr. Dana Skarra will present the data from SenesTech's recent trial in mice. Short-term (15 days) free-choice feeding of bait containing VCD and triptolide, the two active ingredients in ContraPest, SenesTech's EPA registered product for fertility control of rats, suppressed fertility in mice by reducing sperm count to 2.4% of controls and decreasing ovarian function without any observable adverse effect. Forty percent of breeding pairs given access to the treatment bait were infertile, and those that did produce litters averaged only 3 pups per litter compared to the control group, of which 100% were fertile with an average of 7.1 pups per litter.
"These data provide a foundation data set for a potential rodent control specifically for mice," said Dr. Loretta Mayer, CEO and co-founder of SenesTech. "This is further demonstration of our ability to adapt our platform technology to additional species, and is the first step towards the potential of a second SenesTech product, after ContraPest, our first commercially available product that safely and sustainably controls rat infestations."
The 50th Annual Meeting of the Society for the Study of Reproduction will be held July 13-16, 2017 at the Marriott Wardman Park in Washington D.C. SenesTech, Inc. is the sole supporter of the symposium "Recent Developments in Contraception" (S8) at the Platinum level. The SenesTech senior research team will be available during the SSR EXPO at exhibitor booth #14 to talk about the science behind SenesTech's offering.
Dr. Mayer continued, "SenesTech is honored to be a member of this organization, as sound science is the foundation of SenesTech products, and we are grateful for the association with SSR and the critical review they offer to serious scientists. I am looking forward to the meetings and scientific exchanges."
SenesTech developed an innovative technology for managing animal pest populations through fertility control as opposed to a lethal approach. The company's first fertility control product, ContraPest, is marketed for use in controlling rat infestations. ContraPest's novel technology targets the reproductive capabilities of both sexes, inducing egg loss in female rodents and impairing sperm development in males. Using proprietary bait stations, ContraPest is dispensed in a highly palatable liquid formula that promotes sustained consumption by rodent communities. The liquid is biodegradable, designed to be safe for handlers and non-target species such as wildlife, livestock and pets. In contrast, the historical approach to managing rodent pest populations, rodenticides, carries a high risk of environmental contamination and the poisoning of non-target animals, pets and children.
SenesTech's non-lethal approach of targeting reproduction is more humane, environmentally safe, and more effective in providing a sustainable solution to pest management. Currently no other non-lethal fertility control product is approved by the Food and Drug Administration (FDA) and the Environmental Protection Agency (EPA), for the management of rodent populations. SenesTech believes ContraPest will establish a new paradigm over rodenticides, without the negative environmental effects. For more information visit the SenesTech website at www.senestech.com.
About The Society for the Study of Reproduction
The Society for the Study of Reproduction (SSR) was founded in 1967 to promote the study of reproduction by fostering interdisciplinary communication among scientists, holding conferences, and publishing meritorious studies. SSR is an association of scientists and physicians interested in research in reproduction. Some are engaged in basic or applied research, while others perform clinical practice, but all are dedicated to advancing knowledge of reproductive processes in animals and in humans.
Safe Harbor Statement
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors and other risks identified in our filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
Company: Tom Chesterman, Chief Financial Officer, SenesTech, Inc., 928-779-4143
SOURCE SenesTech, Inc.